NewAmsterdam Pharma Co N.V.
Company Stats
- Market Cap
- $2.9B
- as of Sep 30, 2026
- Shares Outstanding
- 119.5M
- Free Float
- 57.8%
Income Statement
- Revenue
- $22.5M
- Operating Income
- -$225.7M
- Net Income
- -$203.8M
- EBITDA
- -$225.5M
- Revenue Growth, 3Y
- -39.7%
- FCF Margin, 3Y Avg
- -669.9%
- FCF Margin, Worst Year
- -1002.4%
Cash Flow
- Free Cash Flow
- -$148.0M
- FCF Yield
- -5.1%
- Owner FCF Yield
- -7.1%
Balance Sheet
- Cash & Equivalents
- $490.0M
Returns & Capital
- SBC, 3Y Avg
- $39.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $22.5M | -$148.0M | -657.8% |
| FY2024 | $45.6M | -$159.2M | -349.5% |
| FY2023 | $14.1M | -$141.2M | -1002.4% |
| FY2022 | $102.7M | $10.4M | 10.2% |
| FY2021 | — | -$29.5M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back